Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 trial of BNT323/DB-1303 versus investigator's choice chemotherapy in previously treated HER2-expressing recurrent endometrial cancer
CTR20252691Phase 3Active
- Sponsor
- AbbVie Inc.
- Start
- Sep 2025
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of trastuzumab pamirtecan in endometrial cancer (EC), sponsored by AbbVie Inc.. Started Sep 2025; status: active.
02
Drugs
trastuzumab pamirtecan
03
Conditions
endometrial cancer (EC)
Beyond the preview
Go deeper on CTR20252691.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20252691.